{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T21:01:11Z","timestamp":1773435671181,"version":"3.50.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The treatment landscape for ovarian cancer has changed in recent years with the introduction of targeted therapies to treat patients with advanced disease. We investigated patient demographic and clinical factors associated with use of targeted therapies as a part of the first-line treatment for ovarian cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study included patients diagnosed with stage I\u2013IV ovarian cancer between 2012 and 2019 from the National Cancer Database. Information on demographic and clinical characteristics were collected and described using frequency and percent across receipt of targeted therapy. Logistic regression was used to compute the odds ratios (ORs) and 95% confidence intervals (CI) associating patient demographic and clinical factors with receipt of targeted therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 99,286 ovarian cancer patients (mean age 62 years), 4.1% received targeted therapy. The rate of targeted therapy receipt across racial and ethnic groups over the study period was fairly similar; however, non-Hispanic Black women were less likely to receive targeted therapy than their non-Hispanic White counterparts (OR=0.87, 95% CI: 0.76\u20131.00). Patients who received neoadjuvant chemotherapy were more likely to receive targeted therapy than those who received adjuvant chemotherapy (OR=1.26; 95% CI: 1.15\u20131.38). Moreover, among patients who received targeted therapy, 28% received neoadjuvant targeted therapy, with non-Hispanic Black women being most likely to receive neoadjuvant targeted therapy (34%) compared with other racial and ethnic groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We observed differences in receipt of targeted therapy by factors such as age at diagnosis, stage, and comorbidities present at diagnosis, as well as factors related to healthcare access\u2014including neighborhood education level and health insurance status. Approximately 28% of patients received targeted therapy in the neoadjuvant setting, which could negatively impact treatment outcomes and survival due to the increased risk of complications associated with targeted therapies that may delay or prevent surgery. These results warrant further evaluation in a cohort of patients with more comprehensive treatment information.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1104630","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T05:44:38Z","timestamp":1683870278000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Sociodemographic disparities in targeted therapy in ovarian cancer in a national sample"],"prefix":"10.3389","volume":"13","author":[{"given":"Saber A.","family":"Amin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay J.","family":"Collin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juraj","family":"Kavecansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soko","family":"Setoguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaya M.","family":"Satagopan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa V.","family":"Bandera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3802\/jgo.2013.24.1.83","article-title":"Advanced ovarian cancer: what should be the standard of care","volume":"24","author":"Goff","year":"2013","journal-title":"J Gynecol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx444","article-title":"Immunotherapy in ovarian cancer","volume":"28","author":"Odunsi","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2583","article-title":"Beyond chemotherapy: targeted therapies in ovarian cancer","volume":"9","author":"Yap","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(11)70155-1","article-title":"The role of targeted therapy in ovarian cancer","volume":"47","author":"Banerjee","year":"2011","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12916-022-02287-3","article-title":"Targeted therapies for cancer","volume":"20","author":"Zhou","year":"2022","journal-title":"BMC Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12926","article-title":"Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2012.0140","article-title":"Ovarian cancer, version 3.2012","volume":"10","author":"Morgan","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0042","article-title":"Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer","volume":"16","author":"Haunschild","year":"2018","journal-title":"Future Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-018-1319-y","article-title":"Bevacizumab combined with platinum\u2013taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)","volume":"24","author":"Komiyama","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-7534(20)32763-0","article-title":"198P - biomarker (BM) results from GOG-0218, a phase 3 trial of front-line bevacizumab (BV) + chemotherapy (CT) for ovarian cancer (OC)","volume":"23","author":"Birrer","year":"2012","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.1075","article-title":"At What cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? a cost-effectiveness analysis","volume":"29","author":"Cohn","year":"2011","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ygyno.2010.02.021","article-title":"Bevacizumab toxicities and their management in ovarian cancer","volume":"117","author":"Randall","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.20517\/2394-4722.2018.25","article-title":"A review of the effects of healthcare disparities on the experience and survival of ovarian cancer patients of different racial and ethnic backgrounds","volume":"5","author":"Kaufman","year":"2019","journal-title":"J Cancer Metastasis Treat"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3182922a17","article-title":"Adherence to treatment guidelines for ovarian cancer as a measure of quality care","volume":"121","author":"Bristow","year":"2013","journal-title":"Obstet Gynecol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.7031","article-title":"Disparities by race, socioeconomic status, and insurance type in the receipt of NCCN guideline concordant care for select cancer types in California","volume":"38","author":"Clair","year":"2020","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt065","article-title":"Disparities in ovarian cancer care quality and survival according to race and socioeconomic status","volume":"105","author":"Bristow","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.03.016","article-title":"Trends in the receipt of guideline care and survival for women with ovarian cancer: a population-based study","volume":"145","author":"Warren","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1200\/EDBK_323523","article-title":"Immune-based cancer treatment: addressing disparities in access and outcomes","author":"Osarogiagbon","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B27","doi-asserted-by":"publisher","first-page":"896","DOI":"10.6004\/jnccn.2019.0039","article-title":"NCCN guidelines insights: ovarian cancer, version 1.2019: featured updates to the NCCN guidelines","volume":"17","author":"Armstrong","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0109","article-title":"Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites","volume":"14","author":"Kobold","year":"2009","journal-title":"Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.6905","article-title":"Using the national cancer database for outcomes research: a review","volume":"3","author":"Boffa","year":"2017","journal-title":"JAMA Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1104630\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T05:44:42Z","timestamp":1683870282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1104630\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":30,"alternative-id":["10.3389\/fonc.2023.1104630"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1104630","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"article-number":"1104630"}}